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Effectiveness of fixed-dose combination therapy in 
hypertension: systematic review and meta-analysis
Paweł Kawalec1, Przemysław Holko1, Małgorzata Gawin2, Andrzej Pilc3
A b s t r a c t
Introduction: Clinical studies have revealed that fixed-dose combinations 
(FDCs) of drugs can have a better effect on blood pressure than free-equiva-
lent combinations (FECs). Our objectives were to perform an up-to-date as-
sessment of the effectiveness of FDCs and FECs in antihypertensive therapy, 
to provide more accurate results by using a stratified meta-analysis.
Material and methods: A systematic review was performed in PubMed, Web 
of Science, and Cochrane databases according to PRISMA guidelines. The 
outcomes were adherence (compliance), persistence to medication, reduc-
tion of blood pressure and the safety profile. We used the Newcastle Ottawa 
scale or the Delphi list for the assessment of the quality of cohort studies or 
clinical trials, respectively. Heterogeneity was assessed using the Cochrane 
Q test and I2 statistic.
Results: Of 301 abstracts screened, 26 primary studies and 2 other meta- 
analyses were identified, of which 12 studies were included in the meta- 
analyses and 3 studies were included in the narrative review. The FDC 
treatment is associated with a significant improvement in adherence and 
persistence in comparison with FEC treatment, e.g., the average medicine 
possession ratio increased with FDC by 13.1% (p < 0.001). For endpoints 
correlated with higher adherence (e.g., a reduction in blood pressure), a non-
significant benefit was observed for FDCs. Moreover, it was demonstrated 
that higher adherence can lead to a lower risk of cardiovascular events.
Conclusions: In comparison with FECs, the FDC treatment is associated with 
a significant improvement in the cooperation between a doctor and a pa-
tient and with increased patients’ adherence to the treatment schedule.
Key words: fixed-dose combinations, free-equivalent combinations, 
hypertension.
Introduction 
Hypertension is a  common condition associated with substantial 
morbidity and mortality. Nowadays, over 1 billion people suffer from high 
blood pressure worldwide [1], and it is estimated that the prevalence of 
hypertension will have risen by an additional 27 million people by the 
year 2030 [2]. Improper management of hypertension can lead to car-
diac failure, stroke, end-stage renal disease, and, finally, to death [3, 4]. 
Although blood pressure lowering is crucial in hypertension, about half 
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of the patients still have uncontrolled blood pres-
sure [5].
The initial approach to blood pressure lower-
ing is based on monotherapy, but in many cases, 
combination therapy is necessary to achieve tar-
get blood pressure levels [6]. Studies that assessed 
the difference in efficacy between monotherapy 
and polytherapy for blood pressure control have 
shown that combination therapy is more effective 
than monotherapy [7, 8]. Combination therapy is 
available either as a fixed-dose combination (FDC), 
which includes at least 2 active agents combined in 
a single pill (also known as a single-pill combina-
tion), or as a free-equivalent combination (FEC, also 
known as a free combination), which involves sepa-
rate use of the corresponding drug components. Al-
though the FEC is chemically equivalent to the FDC, 
a number of studies have indicated that the FDC 
can have a better impact on blood pressure control 
as well as reducing the use of medical resources 
by increasing patients’ adherence (compliance) and 
persistence to treatment [9–12].
Systematic reviews published in 2010 and 
2011 confirmed a significantly higher adherence 
rate among patients treated with an FDC com-
pared with an FEC [12, 13], although without 
a significant impact on blood pressure levels [13]. 
It is noteworthy that previous reviews [12, 13] pro-
vide different conclusions regarding persistence. 
We performed a  systematic review and meta- 
analysis to provide an up-to-date evaluation of the 
effectiveness of FDCs in comparison with FECs in 
patients with hypertension to deliver precise effect 
sizes calculated throughout separate meta-anal-
yses stratified according to the definition of out-
comes related to: adherence, average medicine 
possession ratio (MPR) or average proportion of 
days covered (PDC) or probability of being adher-
ent to treatment (i.e. with MPR or PDC ≥ 80%) or 
stratified according to the period of observation in 
case of persistence, incorporating generally accept-
ed methodological standards (no synthesis of: pro-
spective and retrospective studies, adjusted and 
unadjusted outcomes, or treating the rate of being 
adherent and the adherence rate as the same vari-
able. Moreover, we aimed to provide systematically 
obtained evidence regarding effectiveness of FDCs 
in reducing rates of cardiovascular events.
We finally aimed to solve the problem of con-
flicting conclusions from previous reviews [12, 13] 
regarding higher persistence on FDC treatment in 
comparison with FEC treatment. 
Material and methods
Search strategy and eligibility criteria
A systematic search of the literature was con-
ducted in PubMed, Web of Science, and Cochrane 
Controlled Trial Registry. No date restriction was 
applied to the search and the last search was per-
formed on 14 April 2015. Comprehensive combina-
tions of MeSH and free-text terms were used for the 
literature search to identify studies regarding hy-
pertension, antihypertensive agents, and FDCs. The 
terms were then combined with the terms for the 
outcome of interest, including at least compliance, 
adherence, persistence, and adverse effects. The 
search was conducted according to the Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses (PRISMA) guidelines for systematic liter-
ature reviews and meta-analyses [14]. Potentially 
relevant full-text publications were then screened 
for inclusion against the following predetermined 
criteria: patients with hypertension (population); 
fixed-dose combinations with or without addition-
al drugs (intervention) compared with free-equiva-
lent combinations with or without additional drugs 
(comparison); medication compliance/adherence, 
persistence, adverse events, systolic and diastolic 
arterial blood pressures, and safety of treatment 
as outcomes. No restrictions were applied as to the 
study design. The study was excluded if it did not 
comply with at least one inclusion criterion.
Within the framework of our systematic review, 
apart from primary research publications identified 
during the database search, we also took into con-
sideration publications and conclusions presented 
in previously published systematic reviews [12, 13]. 
Records selected for retrieval were assessed by 
2 independent reviewers for methodological valid-
ity before inclusion in the review using standard-
ized critical appraisal instruments. Any disagree-
ments were resolved through discussion or with 
the third independent reviewer. 
Quality assessment of the included studies was 
done using either the Newcastle-Ottawa scale (co-
hort studies) [15] or the Delphi list (clinical trials) 
[16], and the studies were accordingly categorized 
into the following 4 categories: poor, fair, good, 
and excellent.
Data collection and synthesis
Quantitative data were extracted from papers 
included in the review using the standardized data 
extraction tables. The extracted data included 
specific details about the interventions, patients’ 
characteristics, study design, methods of outcome 
analysis, and results of significance to the review 
questions and specific objectives. Data extraction 
and meta-analysis were conducted independently 
on the basis of all the identified studies providing 
an update and verification of the systematic re-
views [12, 13]. 
Medication adherence (compliance) was de-
fined according to: i) the number of the adminis-
tered tablets as a medicine possession ratio (MPR) 
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estimated on the basis of the number of days of 
medication supply within the prescription refill in-
terval [17–26] or ii) the percentage of days during 
which a medication was taken by patients, on the 
basis of the proportion of days covered (PDC) [27, 
28]. A  compliant (adherent) patient was defined 
as a patient with an MPR or PDC of 80% or higher. 
Persistence was described on the basis of the pre-
scription refill interval as previously described by 
Gupta et al. [13].
We investigated the average estimate of adher-
ence estimators (PDC or MPR), probability of being 
adherent to the prescribed treatment (MPR or PDC 
≥ 80%), effectiveness in blood pressure lowering, 
as well as persistence rates and the rates of ad-
verse events and cardiovascular events among 
all patients treated with an FDC or FEC. The pub-
lication bias was assessed by funnel plots and by 
Egger’s or Begg’s test. Effect sizes were expressed 
as odds ratios (ORs) for dichotomous data and 
weighted mean differences for continuous data. 
The 95% confidence intervals (CIs) were calculat-
ed for all measures. The results for time-to-event 
data were presented as a hazard ratio (if available) 
or as the average or median length of treatment 
calculated with nonparametric or semiparametric 
approaches (Kaplan-Meier or Cox model). 
Standard methods were used for meta-analysis 
(Mantel-Haenszel fixed effect model and DerSi-
monian and Laird random effect model). Hetero-
geneity was assessed using the standard c2 (Co-
chrane Q) test and I2 statistic. The random effects 
model was applied if significant heterogeneity be-
tween studies was revealed (a p-value of less than 
0.1). Heterogeneity between studies was explored 
using subgroup analyses based on different quan-
titative study designs included in this review (pro-
spective vs. retrospective), different measure of 
adherence (MPR vs. PDC), and different follow-up 
periods for dichotomous outcomes. The meta-re-
gression for outcomes reported in more than 
5 studies was also planned as an attempt to ex-
plain the heterogeneity. Where statistical pooling 
was not possible, the findings were presented in 
a narrative form including tables to enhance data 
presentation where appropriate.
All calculations were performed using the soft-
ware R version 3.03 (R Core Team, 2014) and Excel 
2013 (Microsoft). The ‘metafor’ package was used 
within the R environment [29].
Results
The electronic searches yielded 301 unique 
records after duplicates had been removed. The 
selection of titles and abstracts resulted in 34 
potentially relevant articles (32 primary research 
studies and 2 systematic reviews), of which 6 ar-
ticles were excluded (lack of appropriate data to 
use, 1; analysis of other endpoints, 2; inadequate 
comparison, 3). The flow of information through 
the different phases of the systematic review is 
shown in Figure 1.
In a  systematic review by Gupta et al. [13], 
conducted in 2010, 15 studies were taken into ac-
count: 5 randomized studies [17, 30–33] (1 parallel 
trial and 4 crossover trials, 2 double-blinded and 
3 open trials), 4 nonrandomized crossover trials [18, 
34–36], and 6 retrospective cohort studies [19–21, 
37, 38] (a study by Dezii, 2000, presented data for 
2 different treatment schedules, FDC vs. FEC; 
therefore, it was introduced separately). 
In a  systematic review by Sherill et al. [12], 
15 studies were taken into account: 1 randomized 
crossover multicenter study [17], 1 nonrandom-
ized crossover multicenter study [18], and 13 ret-
rospective cohort studies [19–26, 37, 39–42]. 
Six studies [17–21, 37] included in the review by 
Sherrill et al. [12] were also investigated by Gup-
ta et al. [13]. Two studies (Malesker and Hilleman, 
2010 [42], and Barron et al., 2008 [41]), which were 
included by Sherrill et al. [12], were excluded from 
our analysis because they focused on the analysis 
of other endpoints. Two bibliographic records [22, 
23] identified by Sherrill et al. [12] were related to 
the studies included by Gupta et al. [13]. 
In our analysis a conference abstract (Jackson 
et al., 2006 [38]) included in the review by Gupta 
et al. [13] was replaced by a full-text publication 
(Brixner et al. 2008 [22]), which concerned the 
same study although with slight methodological 
changes in data analysis. A  study performed by 
Dickson and Plauschinat, 2008 [23], included data 
collected in the population of people between the 
ages of 18 and 99 years old, while another study 
by Dickson and Plauschinat, 2008 [21], which 
was included in the review by Gupta et al., 2010 
Figure 1. PRISMA flow diagram for selection of 
studies identified in the systematic review
PubMed: 240 records
Web of Science:  
405 records  
Cochrane Library:  
65 records 
301 of records after 
duplicates were removed 
301 of records screened 
34 full-text articles 
assessed for eligibility 
34 studies included:
– Systematic reviews (2)
– Clinical studies (32) 
267 of records excluded 
6 of full-text articles 
excluded:
–  Lack of appropriate 
data (1)
– Other endpoints (2)
– Other comparisons (3)
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[13], contained data collected in the population of 
people between the age of 65 and 99 years old 
(2 samples from the same study’s population).
Six new retrospective studies were identified 
[27, 28, 40, 43–45], but only four met the criteria 
for inclusion in the analysis. Studies by Asplund 
et al. 1984 [17], Kumagai et al. 2013 [44], and Ulu-
soy et al. 2012 [45] were not included in statistical 
pooling because the data reported did not allow 
for their use in the review or the clinical assess-
ment was different in those studies. 
Finally, in our analysis we included data from 
four studies [18–21], which were also taken into 
account by Gupta et al. and Sherrill et al., from 
5 studies [2–14, 17–26, 30–39] which were includ-
ed only by Sherill et al. and from 6 new identified 
studies [3, 27, 28, 43, 44]. 
Characteristics of the identified studies [17–28, 
30–40, 43–45] are shown in Table I.
Adherence
In our analysis 11 retrospective cohort studies 
and 1 nonrandomized trial reporting data on ad-
herence to medication in hypertensive patients 
were taken into account (studies providing infor-
mation on the average MPR or PDC or the number 
of adherent patients in each group). 
A  meta-analysis of the 2 retrospective cohort 
studies that defined being adherent as having an 
MPR of 0.8 or higher demonstrated a significantly 
(p < 0.001) higher percentage of adherent patients 
on FDC treatment in comparison with those on FEC 
treatment (pooled OR at 1.47; 95% CI: 1.23–1.74). 
Similar results were obtained in a meta-analysis 
of the 2 retrospective cohort studies with the PDC 
as the measure of adherence, although with sig-
nificant heterogeneity of effect sizes (p < 0.001). 
A significant increase in the rate of adherence on 
FDC treatment was also obtained in 1 prospective 
clinical trial (p = 0.032; Figure 2).
Nine retrospective cohort studies showed the 
results for the average MPR (4 studies reported 
variances and 4 did not have variances available) 
or PDC values (1 study). A meta-analysis of 4 co-
hort studies demonstrated that using the FDC in-
stead of the FEC was associated with a significant 
increase in the average MPR by absolute 13.1% 
(95% CIs: 8.9–17.2%, p < 0.001). A significant in-
crease in the average PDC was also reported by 
Ferrario et al. (p < 0.001; Figure 3) [28].
Persistence
Data concerning persistence were included in 
the 6 identified studies. One of them [37] was 
previously identified by Gupta et al. [13], and 
four [22, 24, 26, 37] were previously described by 
Sherrill et al. [12]. The sixth study was identified 
in our search. A study by Hasford et al. 2007, in-
cluded by Sherrill et al. [12], was excluded from 
the meta-analysis due to different definitions of 
FDC and FEC in the compared groups [39]. A meta- 
analysis performed only on the basis of retrospec-
tive cohort studies showed significantly higher 
persistence among patients treated with the FDC 
when compared with those treated with the FEC. 
After 6 and 12 months of treatment, the number 
of patients on FDC treatment was significant-
ly higher than that of those on FEC treatment 
(p = 0.024 and p = 0.012, respectively; Figure 4). 
A significant increase in the duration of treatment 
was also identified (p < 0.001; Table II).
Efficacy in blood pressure lowering 
Nine trials included in the systematic review by 
Gupta et al. [13] provided information on blood 
pressure-lowering efficacy, and additionally, three 
of those trials reported the influence on both sys-
tolic and diastolic blood pressures. 
Apart from the studies found by Gupta [13] and 
described in his systematic review, we identified 
three additional clinical trials [43–45] referring to 
blood pressure-lowering efficacy that were includ-
ed in the narrative review – we evaluated the new 
trials and established that they are not eligible to 
be included in the updated meta-analysis. 
In a cohort study performed by Bronsert et al. 
[43], patients receiving FDC treatment in compar-
ison with those receiving FEC treatment showed 
a  significantly greater reduction in systolic blood 
pressure (–5.3 mm Hg; 95% CI: –6.5 to –4.1) and di-
astolic blood pressure (–4.1 mm Hg; 95% CI: –4.8 to 
–3.4). The analysis was adjusted for the difference 
in confounder variables between the compared 
groups. A  significantly higher rate of blood pres-
sure normalization on FDC treatment in compari-
son with FEC treatment was also found (p < 0.001) 
[43]. Kumagai et al. [44] found that home blood 
pressure obtained by treatment was significantly 
lower in patients receiving FDCs than those receiv-
ing FECs, and this was accompanied by increasing 
adherence to medication (p < 0.01). On the other 
hand, Ulusoy et al. [45] demonstrated a reduction 
in all-day, daytime, night-time, and early morning 
systolic and diastolic blood pressures (blood pres-
sure variability) in the FEC group as compared with 
the FDC group. However, the conclusions should 
probably be attributed to the difference in the time 
of administration of FEC compounds in the control 
group (valsartan in the morning and amlodipine 
in the afternoon in the control group; FDC in the 
morning in the study group) [45]. 
Other health outcomes and adverse events 
Unfortunately, as in the case above, we have 
not identified new data on adverse effects, which 
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could be incorporated into the meta-analysis. 
However, Ferrario et al. 2013 [28] reported the re-
sults regarding the prevalence of cardiovascular 
events. The analysis of this retrospective cohort 
study demonstrated that a  significantly lower 
number of patients on FDC treatment experienced 
cardiovascular events compared with patients on 
FEC treatment (OR = 0.31; 95% CI: 0.24–0.39). 
Bias assessment and heterogeneity 
Significant heterogeneity was observed in rela-
tion to all of the endpoints included in the review 
when all studies were pooled (data not shown). 
Subgroup analyses reduced the heterogeneity 
for some outcomes (odds for being adherent to 
treatment as measured with MPR in cohort stud-
ies, differences in average MPR between cohort 
studies), while for others heterogeneity remained 
significant.
A series of univariate and multivariate meta-re-
gression analyses for 2 endpoints was carried out 
(adherence rates and average measure of adher-
ence; 12 studies). The following predictors were 
taken into account: type of the study (prospective 
vs. retrospective), measure of adherence (PDC vs. 
MPR), duration of follow-up, percentage of wom-
en, and mean age of study participants. Based on 
the results obtained from meta-regression analy-
ses, there was no significant effect of any of the 
predictors (data not shown).
The publication bias was not identified, al-
though a  reliable conclusion cannot be drawn 
Study
FDC FEC
Odds ratio (95% CI) 
Events n Events n
Prospective clinical trials
Schweizer et al. 2007 138 138 183 197 21.89 (1.29–370.10) 
Retrospective studies with PDC
Ferrario et al. 2013 2146 4864 1513 7748 3.25 (3.00–3.52)
Zeng et al. 2010 1016 2213 816 2312 1.56 (1.38–1.75) 
Retrospective studies with MPR
Shaya et al. 2009 62 202 79 366 1.61 (1.09–2.37)
Brixner et al. 2008 1011 1638 297 561 1.43 (1.18–1.74)
Retrospective studies with PDC (p = 0.028, REM), heterogeneity:
Q = 101.34, df = 1 (p < 0.001), I2 = 99.1%
2.25 (1.09–4.64)
1.47 (1.23–1.74)
Retrospective studies with MPR (p < 0.001, FEM), heterogeneity: 
Q = 0.27, df = 1 (p = 0.602), I2 = 0.0% 
Figure 2. Meta-analysis of odds ratio for adherence to treatment. Events represent the number of patients meeting 
the definition of adherence (MPR or PDC ≥ 0.8). Odds ratio (OR) presented for FDC in comparison with FEC, with 
95% confidence intervals (CI)
Odds ratio
0.75 1.74 4.05 9.42 21.89
Study
FDC FEC Mean difference 
(95% CI)Mean (SD) n Mean (SD) n
PDC studies
Ferrario et al. 2013 63.0 (34.0) 4864 34.0 (34.0) 7748 29.0 (27.8–30.2)
MPR studies
Jackson et al. 2008 73.1 (NA) 619 60.5 (NA) 65 12.6 (NA–NA)
Hess et al. 2008 76.9 (NA) 7224 54.4 (NA) 7225 25.5 (NA–NA)
Dickson and Plauschinat 2008b 58.6 (NA) 3363 48.1 (NA) 713 10.5 (NA–NA)
Taylor and Shoheiber 2003 80.8 (NA) 2754 73.8 (NA) 2978 7.0 (NA–NA)
Yang et al. 2010 72.8 (NA) 382476 61.3 (NA) 197375 11.5 (11.4–11.6)
Brixner et al. 2008 64.2 (58.7) 1628 57.6 (30.2) 561 6.6 (2.8–10.4)
Dickson and Plauschinat 2008a 63.4 (29.4) 2336 49.0 (23.4) 3368 14.4 (13.0–15.8)
Gerbino and Shoheiber 2004 87.9 (17.0) 2839 69.2 (28.0) 2267 18.7 (17.6–19.8)
MPR studies (p < 0.001, REM), heterogeneity: Q = 173.38, df = 3 (p < 0.001),  
I2 = 98.3% 
13.1 (8.9–17.2) 
Figure 3. Meta-analysis of weighted mean difference in MPR or PDC. Mean difference presented for FDC in com-
parison with FEC, with 95% confidence intervals (CI). Studies not reporting variance for outcomes marked by cross 
estimates
NA – not available.
–10.0 0.0 10.0 20.0 31.0
Mean difference
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owing to the small number of studies. Neither the 
funnel plots nor Egger’s test indicated any associ-
ation between the effect size and study size.
Discussion
A systematic review with a meta-analysis and 
narrative synthesis was conducted to compare 
the effectiveness of the FDC and FEC with re-
gards to adherence (compliance) to medication, 
persistence to medication, and other clinically 
important endpoints during treatment of arterial 
hypertension. The results of the comparison can 
be important for the choice of treatment because 
the majority of patients with hypertension need 
more than 1 drug to control blood pressure. 
Based on the synthesis of direct-comparison 
studies, it was found that FDC treatment is as-
sociated with a  significant improvement in ad-
herence and persistence in comparison with FEC 
treatment. It can be argued that the increase in 
adherence and persistence to FDC treatment in 
comparison with FEC treatment should result in 
a greater reduction in blood pressure and thus in 
obtaining lower blood pressure values. We did not 
identify any clear evidence to confirm this effect. 
The evidence for the benefit of FDCs over FECs 
Study
FDC FEC Odds ratio 
(95% CI) Events n Events n
Assessment at 6 months 
Brixner et al. 2008 1188 1628 157 561 6.95 (5.61–8.61)
Yang et al. 2010 226808 382476 80332 197375 2.12 (2.10–2.15)
Assessment at 12 months
Hess et al. 2008 4212 7224 1077 7225 7.98 (7.37–8.65)
Brixner et al. 2008 879 1628 107 561 4.98 (3.95–6.28)
Dezii 2000b 678 969 405 705 1.73 (1.41–2.11)
Dezii 2000a 1129 1644 361 624 1.60 (1.32–1.93)
Assessment at 6 months (p = 0.024, REM), heterogeneity: 
Q = 117.24, df = 1 (p < 0.001), I2 = 99.2%
3.82 (1.20–12.21)
3.24 (1.30–8.08) 
Assessment at 12 months (p = 0.012, REM), heterogeneity: 
Q = 371.75, df = 3 (p < 0.001), I2 = 99.2%
Figure 4. Meta-analysis of persistence. Events represent the number of patients meeting the definition of per-
sistence. Odds ratio (OR) presented for FDC in comparison with FEC, with 95% confidence intervals (CI)
Odds ratio
0.75 1.50 3.00 6.00 12.00
regarding the blood pressure-lowering effect was 
sparse and indicated only in large cohort studies. 
However, we found direct evidence for the reduc-
tion in the rate of cardiovascular events on FDC 
treatment. 
The reduction in the rate of cardiovascular 
events can be indirectly confirmed by the results 
of 2 studies indicating that patients adherent to 
antihypertensive treatment are experiencing mi-
nor cardiovascular events. In a study that included 
patients with hypertension and without cardiovas-
cular disease at baseline, a reduction in the annu-
al risk of cardiovascular events by 22% (95% CI: 
13–30%) was observed among adherent compared 
with nonadherent patients [46]. Similarly, a study 
that included patients with hypertension and with-
out prior stroke reported a reduction in the risk of 
stroke and death by 8% (95% CI: 4–13%) and 7% 
(95% CI: 4–10%), respectively, among adherent 
versus nonadherent patients [47].
In general, our results are in line with the pre-
viously published systematic reviews by Sherrill 
et al. 2011 [12] and Gupta et al. 2010 [13], although 
some changes were observed, especially when 
comparing the conclusions with the latter study. 
Table II. Clinical efficacy (continuous endpoints) of fixed-dose combinations (FDC) compared with free-equivalent 
combinations (FECs): persistence defined as average duration of treatment
Study FDC group 
Mean ± SD 
(N)
FEC group 
Mean ± SD 
(N)
Effect size
(95% CI)
P-value
Zeng et al. 2010 [35] 215.56 ± NA
(2213)
174.48 ± NA
(2312)
HR = 0.66 
(0.63–0.70)
< 0.001
Ferrario et al. 
2013 [36]
339.76 ±224.08
(2146)
233.72 ±238.56
(1513)
MD = 106.04 
(90.90–121.18)
< 0.001
HR – hazard ratio, MD – mean difference, NA – not available.
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Sherrill et al. 2011 [12] demonstrated signifi-
cantly higher adherence to treatment in the FDC 
group compared with the FEC group, based on 
a meta-analysis of studies reporting average MPR 
in the groups (13.31%, 95% CI: 8.26–18.35%).
Likewise, Gupta et al. [13] revealed that the ad-
herence ratio in the FDC group was 1.2 times high-
er than that in the FEC group. However, they found 
that an increase in adherence was not statisti-
cally significant according to the pooled results 
of prospective trials, had borderline significance 
according to the pooled results of cohort studies, 
and was statistically significant according to the 
pooled results of all studies – prospective and ret-
rospective combined [13].
Similarly, Bangalore et al. 2007 [48] found that 
FDC treatment decreased the risk of medication 
noncompliance in patients with hypertension, tu-
berculosis, diabetes, and human immunodeficien-
cy virus.
Considering patient’s persistence measured 
by the prescription refill interval and as duration 
of treatment, a significant advantage of FDC over 
FEC was identified. This is in line with the results 
reported by Sherrill et al. 2011 [12] (pooled risk 
ratio for 5 studies at 2.13; 95% CI: 1.11–4.09), but 
not with those reported by Gupta et al., 2010 [13], 
who found no statistically significant differences 
between the FDC and FEC groups (pooled OR for 
3 studies at 1.54; 95% CI: 0.95–2.49). These dis-
crepancies might have been caused by the inclu-
sion of a greater number of studies in our anal-
ysis compared with the analysis by Gupta et al. 
[13], the replacement of data from the conference 
abstract (Jackson et al. 2006 [38]) by the full-text 
publication (Brixner et al. 2008 [22]), or by the 
bias in data extraction or analysis (effect size es-
timation and description) in the meta-analysis 
previously published by Gupta et al. [13]. Inter-
estingly, Hasford et al. 2007 demonstrated that 
persistence was the longest for FDCs of angioten-
sin receptor blockers than for FDCs of other drug 
classes. After 3 years of follow-up, 17.7% of the 
patients in the FDC group and only 3.2% of those 
in the FEC group were still on the initial treatment, 
although differences in active substances used in 
both arms were identified [39]. 
The meta-analysis by Gupta et al. showed 
a  nonsignificant decline in the rates of adverse 
effects associated with the use of the FDC as com-
pared with the use of the FEC (OR = 0.80; 95% CI: 
0.58–1.11) [13]. We have found no new evidence 
on the safety profile, so the results presented by 
Gupta et al. 2010 [13] seem to be currently valid, 
and therefore we did not perform a meta-analy-
sis regarding this endpoint. Only 1 retrospective 
study provided evidence concerning the incidence 
of cardiovascular events in the compared groups. 
The results for blood pressure and cardiovascular 
events should be interpreted with caution owing 
to the absence of other studies reporting data 
on these outcomes. We relied on the results of 
retrospective nonrandomized studies, which by 
definition have less credibility than prospective 
randomized clinical trials. On the other hand, re-
liable randomized clinical trials will be difficult to 
conduct for adherence-based therapies.
As for the reduction in systolic and diastolic 
blood pressures and normalization of blood pres-
sure, no new study that could expand the meta- 
analysis by Gupta et al. 2010 [13] was identi-
fied. Instead, 2 large retrospective cohort studies 
by Bronsert et al., 2013 [43], and Kumagai et al., 
2013 [44], were found. Both studies indicated that 
blood pressure was significantly lower in patients 
receiving FDC treatment than in those receiving 
FEC treatment. However it should be noted that 
Gupta et al. [13] found a higher but not statisti-
cally significant (p > 0.05) difference between the 
FDC and FEC in the reduction of both systolic and 
diastolic arterial blood pressures (–4.1 mm Hg; 
95% CI: –9.8 to 1.5 and –3.1 mm Hg; 95% CI: –7.1 
to 0.9, respectively). The probability of normal-
ization of blood pressure was also comparable 
(p > 0.05) in both groups [13]. 
Although some contradictory conclusions were 
obtained by Ulusoy et al. [45] (lower blood pres-
sure variability during FEC treatment than during 
FDC treatment, which could result in a  reduced 
rate of cardiovascular events), the finding on the 
advantage of FDC over FEC regarding cardiovas-
cular events diminished the significance of that 
effect. 
In general, the major limitation of our review is 
the fact that the conclusions were mainly based 
on the results of retrospective cohort studies 
owing to the lack of adequate randomized tri-
als. Moreover, the studies were characterized by 
high heterogeneity in terms of methodology and 
clinical approach. The absence of conformity for 
possible disturbing factors in the event of some 
observational studies and nonrandomized trials in 
our meta-analysis is another limitation. Similarly, 
the included studies did not take into account the 
presence of comorbidities and concomitant ther-
apies. All these limitations may have affected our 
results. However, we did not aggregate results of 
studies with significant differences in design and 
outcomes, thus providing reliable estimates of ef-
fect sizes. 
In conclusion, this systematic review besides 
updating the previous results for comparison of 
the effectiveness of FDCs and FECs in hyperten-
sive patients also provides more accurate results 
through the use of a separate meta-analysis strat-
ified in view of the definition of outcomes related 
to adherence or period of observation in case of 
persistence and additionally assessments of the 
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impact of FDCs on incidence of cardiovascular 
events. 
Our analysis demonstrated that administration 
of the FDC for antihypertensive treatment is asso-
ciated with a statistically significant improvement 
in the cooperation between a  doctor and a  pa-
tient in comparison with FECs (increased adher-
ence and persistence to the treatment schedule). 
It was shown that the use of FDCs of hypertensive 
agents may have a positive effect on blood pres-
sure and is associated with a lower risk of cardio-
vascular events compared with the use of FECs, 
although clear evidence was sparse. 
Well-designed randomized trials are needed to 
confirm our findings and to present a direct quan-
titative link between an increase in adherence or 
persistence to medication and clinically relevant 
outcomes such as the rate of cardiovascular events. 
The introduction of FDC drugs to the standard 
treatment of hypertension could improve the 
quality of life and even provide additional benefits 
such as a  reduced risk of cardiovascular events 
due to elevated adherence and persistence to the 
treatment. 
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